Brain Tumor Reports
48

Volume 19 Number 10
October 2017


Home > Publications > Brain Tumor Reports > Volume 19, Year 2017 > Number 10, October


CONTENTS



BRAIN TUMORS

DIFFUSE ASTROCYTIC AND OLIGODENDROGLIAL TUMORS
- Glioblastoma
- Anaplastic oligodendroglioma

GLIOMAS
- Brain stem gliomas
- - Diffuse intrinsic pontine gliomas
- High-grade gliomas
- Low-grade gliomas

EMBRYONAL TUMORS
- Medulloblastoma





BRAIN TUMORS



DeWitt JC, Mock A, Louis DN.
The 2016 WHO classification of central nervous system tumors: what neurologists need to know.
Curr Opin Neurol. 2017 Sep 9. doi: 10.1097/WCO.0000000000000490. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Hocking MC, Hobbie W, Fisher MJ.
Development of the Pediatric Neuro-Oncology Rating of Treatment Intensity (PNORTI).
J Neurooncol. 2017 Sep 8. doi: 10.1007/s11060-017-2618-2. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Mardaga S, Al Bassir M, Bracke J, Dutilleux A, Born JD.
[Which psychiatric symptoms must raise suspicion about a possible brain tumor ?]
Rev Med Liege. 2017 Sep;72(9):399-405. French.
Source | Abstract | Full text | Similar articles



DIFFUSE ASTROCYTIC AND OLIGODENDROGLIAL TUMORS



Ranjan S, Warren KE.
Gliomatosis Cerebri: Current Understanding and Controversies.
Front Oncol. 2017 Aug 7;7:165. doi: 10.3389/fonc.2017.00165. eCollection 2017.
Source | Abstract | Full text | Similar articles




Sasaki H, Yoshida K.
Treatment Recommendations for Adult Patients with Diffuse Gliomas of Grades II and III According to the New WHO Classification in 2016.
Neurol Med Chir (Tokyo). 2017 Aug 25. doi: 10.2176/nmc.ra.2017-0071. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



GLIOBLASTOMA



Badruddoja MA, Pazzi M, Sanan A, Schroeder K, Kuzma K, Norton T, Scully T, Mahadevan D, Ahmadi MM.
Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma.
Cancer Chemother Pharmacol. 2017 Aug 14. doi: 10.1007/s00280-017-3405-7. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Barney C, Shukla G, Bhamidipati D, Palmer JD.
Re-irradiation for recurrent glioblastoma multiforme.
Chin Clin Oncol. 2017 Aug;6(4):36. doi: 10.21037/cco.2017.06.18.
Source | Abstract | Full text | Similar articles




Burri SH, Gondi V, Brown PD, Mehta MP.
The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists.
Am J Clin Oncol. 2017 Aug 24. doi: 10.1097/COC.0000000000000395. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Grossman SA, Kleinberg L.
A search for the "Goldilocks zone" with regard to the optimal duration of adjuvant temozolomide in patients with glioblastoma.
Neuro Oncol. 2017 Aug 1;19(8):1019-1020. doi: 10.1093/neuonc/nox046.
Comment on: Blumenthal DT et al., Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.
Source | Abstract | Full text | Similar articles




Hassanzadeh C, Rao YJ, Chundury A, Rowe J, Ponisio MR, Sharma A, Miller-Thomas M, Tsien CI, Ippolito JE.
Multiparametric MRI and [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging Is a Potential Prognostic Imaging Biomarker in Recurrent Glioblastoma.
Front Oncol. 2017 Aug 18;7:178. doi: 10.3389/fonc.2017.00178. eCollection 2017.
Source | Abstract | Full text | Similar articles




Kaloshi G, Petrela M.
Letter to the Editor. An extent of resection threshold for recurrent glioblastoma: why wait until recurrence?
J Neurosurg. 2017 Aug 18:1. doi: 10.3171/2017.6.JNS14868. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Kim WJ, Newman WC, Amankulor NM.
Phase I/II Trial of Combination of Temozolomide Chemotherapy and Immunotherapy With Fusions of Dendritic and Glioma Cells in Patients With Glioblastoma.
Comment on: Akasaki Y et al (2016), Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma.
Neurosurgery. 2017 Jul 1;81(1):N11. doi: 10.1093/neuros/nyx263.
Source | Abstract | Full text | Similar articles




Li G, Bonamici N, Dey M, Lesniak MS, Balyasnikova IV.
Intranasal delivery of stem cell-based therapies for the treatment of brain malignancies.
Expert Opin Drug Deliv. 2017 Sep 18:1-10. doi: 10.1080/17425247.2018.1378642. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Orzan F, De Bacco F, Crisafulli G, Pellegatta S, Mussolin B, Siravegna G, D'ambrosio A, Comoglio PM, Finocchiaro G, Boccaccio C.
Genetic Evolution of Glioblastoma Stem-like Cells from Primary to Recurrent Tumor.
Stem Cells. 2017 Sep 12. doi: 10.1002/stem.2703. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Paisan GM, Buell TJ, Raper D, Asthagiri A.
Lumbosacral Subdural Hematoma After Glioblastoma Multiforme Resection: Possible Radiographic Evidence for the Downward Migration of Intracranial Blood.
World Neurosurg. 2017 Sep 7. pii: S1878-8750(17)31499-7. doi: 10.1016/j.wneu.2017.08.189. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Saito T, Sugiyama K, Hama S, Yamasaki F, Takayasu T, Nosaka R, Muragaki Y, Kawamata T, Kurisu K.
Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients.
Neurosurg Rev. 2017 Sep 9. doi: 10.1007/s10143-017-0903-3. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Scoccianti S, Krengli M, Marrazzo L, Magrini SM, Detti B, Fusco V, Pirtoli L, Doino D, Fiorentino A, Masini L, Greto D, Buglione M, Rubino G, Lonardi F, Migliaccio F, Marzano S, Santoni R, Ricardi U, Livi L.
Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO).
Radiol Med. 2017 Sep 6. doi: 10.1007/s11547-017-0806-y. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Stritzelberger J, Distel L, Buslei R, Fietkau R, Putz F.
Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine.
Clin Transl Oncol. 2017 Aug 20. doi: 10.1007/s12094-017-1743-x. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Zhu JJ, Demireva P, Kanner AA, Pannullo S, Mehdorn M, Avgeropoulos N, Salmaggi A, Silvani A, Goldlust S, David C, Benouaich-Amiel A; Zvi Ram on behalf of the EF-14 Trial Investigators.
Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.
J Neurooncol. 2017 Aug 28. doi: 10.1007/s11060-017-2601-y. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



ANAPLASTIC OLIGODENDROGLIOMA



Kumar A A, Abraham Koshy A.
Regression of Recurrent High-Grade Glioma with Temozolomide, Dexamethasone, and Levetiracetam: Case Report and Review of the Literature.
World Neurosurg. 2017 Sep 1. pii: S1878-8750(17)31437-7. doi: 10.1016/j.wneu.2017.08.136. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



GLIOMAS



Li G, Qin Z, Chen Z, Xie L, Wang R, Zhao H.
Tumor Microenvironment in Treatment of Glioma.
Open Med (Wars). 2017 Aug 12;12:247-251. doi: 10.1515/med-2017-0035. eCollection 2017.
Source | Abstract | Full text | Similar articles




Wesseling P, Capper D.
WHO 2016 Classification of Gliomas.
Neuropathol Appl Neurobiol. 2017 Aug 16. doi: 10.1111/nan.12432. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



BRAIN STEM GLIOMAS



Ishihara M, Yamamoto K, Miwa H, Nishi M.
Spontaneous complete regression of a brain stem glioma pathologically diagnosed as a high-grade glioma.
Childs Nerv Syst. 2017 Aug 14. doi: 10.1007/s00381-017-3570-3. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Phuong PC, Hung NQ, Ngoc TB, Rades D, Khoa MT.
Rotating Gamma System Irradiation: A Promising Treatment for Low-grade Brainstem Gliomas.
In Vivo. 2017 Sep-Oct;31(5):957-960.
Source | Abstract | Full text | Similar articles



Diffuse intrinsic pontine gliomas



Galldiks N, Stegmayr C, Willuweit A, Langen KJ.
Positron emission tomography imaging in diffuse intrinsic pontine glioma.
Ann Transl Med. 2017 Aug;5(15):312. doi: 10.21037/atm.2017.05.02.
Source | Abstract | Full text | Similar articles




Kossatz S, Carney B, Schweitzer M, Carlucci G, Miloushev VZ, Maachani UB, Rajappa P, Keshari KR, Pisapia D, Weber WA, Souweidane MM, Reiner T.
Biomarker-Based PET Imaging of Diffuse Intrinsic Pontine Glioma in Mouse Models.
Cancer Res. 2017 Apr 15;77(8):2112-2123. doi: 10.1158/0008-5472.CAN-16-2850. Epub 2017 Jan 20.
Source | Abstract | Full text | Similar articles



HIGH-GRADE GLIOMAS



Xu W, Li T, Gao L, Zheng J, Shao A, Zhang J.
Efficacy and safety of long-term therapy for high-grade glioma with temozolomide: A meta-analysis.
Oncotarget. 2017 Apr 24;8(31):51758-51765. doi: 10.18632/oncotarget.17401. eCollection 2017 Aug 1.
Source | Abstract | Full text | Similar articles



LOW-GRADE GLIOMAS



Choucair AK.
Low grade glioma: a journey towards a cure.
Chin Clin Oncol. 2017 Aug;6(4):43. doi: 10.21037/cco.2017.07.08.
Source | Abstract | Full text | Similar articles




Mora J, Perez-Jaume S, Cruz O.
Treatment of childhood astrocytomas with irinotecan and cisplatin.
Clin Transl Oncol. 2017 Aug 21. doi: 10.1007/s12094-017-1741-z. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



EMBRYONAL TUMORS


MEDULLOBLASTOMA



Belcher SM, Burton CC, Cookman CJ, Kirby M, Miranda GL, Saeed FO, Wray KE.
Estrogen and soy isoflavonoids decrease sensitivity of medulloblastoma and central nervous system primitive neuroectodermal tumor cells to chemotherapeutic cytotoxicity.
BMC Pharmacol Toxicol. 2017 Sep 6;18(1):63. doi: 10.1186/s40360-017-0160-7.
Source | Abstract | Full text | Similar articles




Scobioala S, Parfitt R, Matulat P, Kittel C, Ebrahimi F, Wolters H, Am Zehnhoff-Dinnesen A, Eich HT.
Impact of radiation technique, radiation fraction dose, and total cisplatin dose on hearing : Retrospective analysis of 29 medulloblastoma patients.
Strahlenther Onkol. 2017 Sep 8. doi: 10.1007/s00066-017-1205-y. [Epub ahead of print]
Source | Abstract | Full text | Similar articles